UBS Group
VIR icon

UBS Group’s Vir Biotechnology VIR Stock Holding History

UBS Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.7M Sell
461,334
-282,808
-38% -$2.69M ﹤0.01% 4224
2026
Q1 		$6.67M Buy
744,142
+326,177
+78% +$2.6M ﹤0.01% 3768
2025
Q4 		$2.52M Buy
417,965
+203,203
+95% +$1.21M ﹤0.01% 4744
2025
Q3 		$1.23M Sell
214,762
-100,405
-32% -$513K ﹤0.01% 5389
2025
Q2 		$1.59M Sell
315,167
-162,229
-34% -$870K ﹤0.01% 5038
2025
Q1 		$3.09M Buy
477,396
+237,283
+99% +$2.11M ﹤0.01% 4284
2024
Q4 		$1.76M Sell
240,113
-143,075
-37% -$1.13M ﹤0.01% 4839
2024
Q3 		$2.87M Buy
383,188
+89,713
+31% +$779K ﹤0.01% 3644
2024
Q2 		$2.61M Sell
293,475
-172,733
-37% -$1.66M ﹤0.01% 3486
2024
Q1 		$4.72M Sell
466,208
-59,972
-11% -$611K ﹤0.01% 3039
2023
Q4 		$5.29M Buy
526,180
+240,648
+84% +$2.2M ﹤0.01% 2731
2023
Q3 		$2.68M Buy
285,532
+74,704
+35% +$1.07M ﹤0.01% 3165
2023
Q2 		$5.17M Buy
210,828
+88,702
+73% +$2.23M ﹤0.01% 2555
2023
Q1 		$2.84M Sell
122,126
-167,601
-58% -$4.29M ﹤0.01% 3050
2022
Q4 		$7.33M Buy
289,727
+185,199
+177% +$4.54M ﹤0.01% 2147
2022
Q3 		$2.02M Sell
104,528
-22,347
-18% -$568K ﹤0.01% 3156
2022
Q2 		$3.23M Sell
126,875
-194,178
-60% -$4.53M ﹤0.01% 2733
2022
Q1 		$8.26M Buy
321,053
+225,346
+235% +$6.68M ﹤0.01% 2086
2021
Q4 		$4.01M Buy
95,707
+75,375
+371% +$2.95M ﹤0.01% 3068
2021
Q3 		$884K Sell
20,332
-1,459
-7% -$63.2K ﹤0.01% 4293
2021
Q2 		$1.03M Sell
21,791
-13,185
-38% -$599K ﹤0.01% 4147
2021
Q1 		$1.79M Sell
34,976
-10,515
-23% -$567K ﹤0.01% 3667
2020
Q4 		$1.22M Sell
45,491
-19,930
-30% -$648K ﹤0.01% 3858
2020
Q3 		$2.25M Buy
65,421
+27,993
+75% +$1.21M ﹤0.01% 2940
2020
Q2 		$1.53M Buy
37,428
+33,241
+794% +$1.12M ﹤0.01% 3133
2020
Q1 		$143K Sell
4,187
-7,770
-65% -$209K ﹤0.01% 4984
2019
Q4 		$150K Buy
+11,957
New +$160K ﹤0.01% 5782

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

UBS Group's VIR Position: Q2 2026 in Review

UBS Group reduced its Vir Biotechnology (VIR) stake by 38% in Q2 2026, selling an estimated $2.69M and leaving 461,334 shares worth $4.7M. The position accounts for ﹤0.01% of the portfolio, ranked #4224.

UBS Group first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $8.26M in Q1 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • UBS Group held 461,334 shares of Vir Biotechnology worth $4.7M as of Q2 2026.
  • UBS Group sold 282,808 Vir Biotechnology shares in Q2 2026, an estimated $2.69M.
  • Vir Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4224 holding.
  • UBS Group first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • UBS Group's Vir Biotechnology position peaked at $8.26M in Q1 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.